(FILE 'HOME' ENTERED AT 11:37:05 ON 20 DEC 2002)

FILE 'MEDLINE, CANCERLIT, BIOTECHDS, CAPLUS, EMBASE' ENTERED AT 11:38:41
ON 20 DEC 2002

L1	1301	S	POLYDENTATE
L2	3599481	S	DNA OR NUCLEIC ACID OR GENE OR VECTOR
L3	22	S	L1 AND L2
L4	13	DUP REM	L3 (9 DUPLICATES REMOVED)
L5	682114	S	CARRIER OR VECTOR
L6	10	S	L5 AND L1
L7	9	DUP REM	L6 (1 DUPLICATE REMOVED)
L8	1	S	L1 AND POLYLYSINE
L9	115213	S	GENE DELIVERY OR GENE THERAPY OR DNA TRANSFE?
L10	0	S	L9 AND L1
L11	76929	S	CROWN ETHER OR POLYETHER
L12	15	S	L11 AND POLYLYSINE
L13	15	DUP REM	L12 (0 DUPLICATES REMOVED)
L14	1084	S	L11 AND L5
L15	64	S	L14 AND L2
L16	55	DUP REM	L15 (9 DUPLICATES REMOVED)
L17	6	S	L16 AND L9
L18	6	DUP REM	L17 (0 DUPLICATES REMOVED)

```
his

     (FILE 'HOME' ENTERED AT 11:54:04 ON 20 DEC 2002)

     FILE 'MEDLINE, CANCERLIT, CAPLUS, EMBASE, BIOTECHDS' ENTERED AT 11:54:18
     ON 20 DEC 2002
L1          4035 S CRYPTA?
L2        115213 S GENE THERAPY OR GENE DELIVERY OR DNA TRANSFE?
L3             5 S L2 AND L1
L4             2 DUP REM L3 (3 DUPLICATES REMOVED)
L5             0 S L1 AND CRIPTATE#
L6             0 S L1 AND CRIPTAT?
L7             0 S CRIPTATES
L8             0 S CRIPTATE
```

L13 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2002 ACS
AN 2000:68361 CAPLUS
DN 132:127724
TI Chelating systems for use in the delivery of compounds to cells
IN Wolff, Jon A.
PA Mirus Corporation, USA
SO PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000003738	A1	20000127	WO 1999-US16095	19990716
	W: JP				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 1098667	A1	20010516	EP 1999-935616	19990716
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI	US 1998-93230P	P	19980717		
	WO 1999-US16095	W	19990716		

AB Chelator contg. compds. are utilized in the delivery of mols., polymers, nucleic acids and genes to animal cells. At least one chelator such as **crown ether** is attached to a polymer and then assocd. with another polymer such as DNA. An ion is then added to the mixt. thereby forming condensed DNA. In condensed form and in complex with the chelator, DNA can be delivered to a cell. Polyacrylamidobenzo-18-crown-6 was prepd. and cation binding as well as interaction with **polylysine** and DNA of this **crown ether** was studied.

L13 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2002 ACS
AN 1997:479337 CAPLUS
DN 127:99879
TI Conjugates of drugs with peptides and polyethers
IN Sinn, Hannsjoerg; Maier-Borst, Wolfgang; Schrenk, Hans-Hermann; Stehle, Gerd; Fiebig, Heinz-H.
PA Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts, Germany
SO Ger. Offen., 8 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19548114	A1	19970626	DE 1995-19548114	19951221
	DE 19548114	C2	20000427		
	WO 9723240	A2	19970703	WO 1996-DE2487	19961220
	WO 9723240	A3	19971009		
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 952853	A2	19991103	EP 1996-946222	19961220
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
	JP 2000502109	T2	20000222	JP 1997-523224	19961220
	US 6395254	B1	20020528	US 1999-308103	19990504
PRAI	DE 1995-19548114	A	19951221		
	WO 1996-DE2487	W	19961220		

AB The title conjugates facilitate the uptake of drugs and their enrichment in tissues (e.g., tumors, inflamed tissues). The peptides contain preferably 7-30 amino acid residues. The polyethers are preferably of 2000-5000 mol. wt.; these confer good water soly. on the product. Such conjugates have the advantage of being nonimmunogenic. A description is given of a conjugate composed of **polylysine**, 8 mols of aminofluorescein, 4 mols. of methoxy polyethyleneglycol, and 2 mols. of 111In-labeled DTPA, which was used as a scintigraphic agent that was selectively taken up by tumor tissue in rats.

L4 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2002 ACS
AN 2002:669607 CAPLUS
DN 137:211893
TI Nucleosides comprising **polydentate** ligands
IN Meade, Thomas J.; Welch, Thomas W.
PA Molecular Dynamics, Inc., USA
SO U.S., 40 pp., Cont.-in-part of U.S. Ser. No. 659,987, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6444423	B1	20020903	US 1998-191785	19981113
PRAI	US 1996-475051	A1	19960607		
	US 1996-659987	B2	19960607		

AB The present invention provides for the selective covalent modification of nucleic acids with redox active moieties such as transition metal complexes. Electron donor and electron acceptor moieties are covalently bound to the ribose-phosphate backbone of a **nucleic acid** at predetd. positions. The resulting complexes represent a series of new derivs. that are bimol. templates capable of transferring electrons over very large distances at extremely fast rates. These complexes possess unique structural features which enable the use of an entirely new class of bioconductors and photoactive probes.

L4 ANSWER 5 OF 13 BIOTECHDS COPYRIGHT 2002 THOMSON DERWENT AND ISI
AN 2001-02530 BIOTECHDS
TI In vitro cleavage of **nucleic acid** sequence useful to prepare smaller nucleotide fragments for cloning, involves contacting the sequence to be cleaved with cationic dinuclear metal complex with **polydentate** ligands;
DNA cleavage and RNA cleavage method for use in diagnosis and therapy
AU Que Jr L; Hanson R S; Schnaith L M T
PA Univ.Minnesota
LO Minneapolis, MN, USA.
PI US 6143879 7 Nov 2000
AI US 1998-123848 28 Jul 1998
PRAI US 1998-123848 28 Jul 1998
DT Patent
LA English
OS WPI: 2001-006446 [01]
AB An in vitro method (I) for cleaving a nucleotide sequence (NS) involves contacting (NS) to be cleaved with a cationic dinuclear metal complex with one or two **polydentate** ligands to cleave NS in its phosphate backbone to form a hydroxyl end and a phosphate end, where the **polydentate** ligand is tethered to a NS recognition element. (I) is used for **DNA** cleavage or RNA cleavage, preferably sequence-specific cleavage i.e. site-specific cleavage, to give smaller nucleotide fragments for cloning, sequencing, and other molecular biology applications. (I) is useful as a diagnostic tool for detecting certain **DNA** or RNA viruses such as hepatitis virus, measles virus and to detect specific genes e.g. oncogenes and other genes associated with specific genetic abnormalities in biological fluid or tissue samples, and as therapeutic tools to destroy target molecules, e.g. viruses and oncogenes. (I) is performed in the presence of a dioxygen source such as oxygen or hydrogen peroxide in the presence of a reductant and NS to be cleaved is a ds **DNA** supercoiled sequence and the cleavage is ds cleavage effective to give linear **DNA**. (18pp)

L4 ANSWER 9 OF 13 BIOTECHDS COPYRIGHT 2002 THOMSON DERWENT AND ISI
AN 1998-02535 BIOTECHDS
TI Nucleic acids covalently modified with electron donors and acceptors; **DNA** probe for use in hybridization, diagnostic or bioconductor
AU Meade T J; Welch T W
PA California-Inst.Technol.
LO Pasadena, CA, USA.
PI WO 9746568 11 Dec 1997
AI WO 1997-US9739 4 Jun 1997
PRAI US 1996-659987 7 Jun 1996
DT Patent
LA English
OS WPI: 1998-042109 [04]
AB A nucleoside containing a covalently attached **polydentate** ligand (CAPL) is claimed. The ligand is attached at the 2' or 3' position of the nucleoside. Also claimed are: a phosphoramidite nucleoside containing a CAPL; a composition of a nucleoside containing a CAPL, where the nucleoside is covalently attached to control pore glass (CPG); a composition of an oligonucleotide (oligo) covalently attached to CPG, where at least 1 nucleoside of the oligo is **polydentate** -modified; a composition of nucleoside, oligo or phosphoramidite nucleoside with a transition metal chelated to the **polydentate** nucleoside; a ss **nucleic acid** containing at least 1 electron donor and at least 1 electron acceptor attached via **polydentate** nucleoside, a terminal base or the 2' or 3' position of a ribose of the ribose-phosphate backbone; a composition of a ss **nucleic acid** containing at least 1 electron donor and a ss **nucleic acid** with at least 1 electron acceptor; production of **nucleic acid** with electron transfer moiety attached; and detecting a target sequence by hybridizing a ss **nucleic acid** containing at least 1 electron donor and electron acceptor. (81pp)

WEST

Freeform Search

Database: US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Term: L31 and l12

Display: 10 **Documents in Display Format:** - **Starting with Number** 1

Generate: ○ Hit List ◉ Hit Count ○ Side by Side ○ Image

Search | Clear | Help | Logout | Interrupt

Main Menu | Show S Numbers | Edit S Numbers | Preferences | Cases

Search History

DATE: Friday, December 20, 2002 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ			
L32	L31 and l12	9	L32
L31	L30 with l8	38	L31
L30	L29 with l23	349	L30
L29	polycationic or polymer	1398472	L29
L28	L27 with l5	14	L28
L27	L23 with l8	713	L27
L26	l24 and l12	2	L26
L25	l24 same l12	0	L25
L24	L23 with (polylysine or polyamine)	50	L24
L23	chelator	7054	L23
L22	L21	3	L22
L21	l20 with l5	3	L21
L20	L19 with (polylysine or polyamine)	240	L20
L19	EDTA	64247	L19
L18	L17 with l4	7	L18
L17	coordination sphere	465	L17
L16	l4 with more than	0	L16
L15	l12 and l11	3	L15
L14	l12 same l11	0	L14
L13	L12 with l11	0	L13
L12	gene therapy or gene delivery or gene transfe$	29892	L12
L11	l7 with l4	48	L11
L10	l8 same l6	2	L10
L9	L8 with l6	0	L9
L8	dna or plasmid or nucleic or gene or polynucleotide	262918	L8
L7	dna or plasmid or nucleic or gene or polynucleotide	262918	L7
L6	L5 with l4	421	L6
L5	conjugated or complexed or electro$	1599359	L5
L4	polydentate ligand or crown ether	7465	L4
L3	6143879.pn.	2	L3
L2	6444423.pn.	1	L2
L1	6395254.pn.	2	L1

END OF SEARCH HISTORY